Back to Interventions
Substance / Medication

Norgestimate

SNOMED 126115000UMLS C0068992

Overview

Active Ingredient
norgestimate
RxNorm CUI
31994

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Female infertility

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

Thyrotropin

LOINC 3016-3

secondary

Estradiol

LOINC 2243-4

primary

Testosterone

LOINC 2986-8

primary

Clinical Trials

2 trials linked to this intervention

2
Total Trials
0
Recruiting
2
With Results

Recent Trials

Study to Evaluate Cycle Control With Norgestimate/Ethinyl Estradiol and Drospirenone/Ethinyl Estradiol in Healthy Sexually Active Females

NCT00745901Phase 4Completed355 enrolled

An Efficacy and Safety Study Comparing Oral Contraceptive Containing Norgestimate or Desogestrel for Acne Treatment

NCT01466673Phase 4Completed201 enrolled
View all 2 trials on ClinicalTrials.gov

Research Evidence

Published studies and systematic reviews

Sort:
Dolutegravir Has No Effect on the Pharmacokinetics of Oral Contraceptives With Norgestimate and Ethinyl Estradiol.
Song Ivy H, Borland Julie, Chen Shuguang et al. · Ann Pharmacother · 2015
PMID: 25862012RCTFull text (PMC)
Effect of saxagliptin on the pharmacokinetics of the active components of Ortho-Cyclen(®), a combined oral contraceptive containing ethinyl estradiol and norgestimate, in healthy women.
Upreti V V, Hsiang C B, Li L et al. · Diabetes Obes Metab · 2012
PMID: 22776778RCT
Effect of raltegravir on estradiol and norgestimate plasma pharmacokinetics following oral contraceptive administration in healthy women.
Anderson Matt S, Hanley William D, Moreau Allison R et al. · Br J Clin Pharmacol · 2011
PMID: 21395656RCTFull text (PMC)
The effects of oral contraceptives on androgen levels and their relevance to premenstrual mood and sexual interest: a comparison of two triphasic formulations containing norgestimate and either 35 or 25 microg of ethinyl estradiol.
Greco Teri, Graham Cynthia A, Bancroft John et al. · Contraception · 2007
PMID: 17586130RCT
Effects of an oral contraceptive (norgestimate/ethinyl estradiol) on bone mineral density in adolescent females with anorexia nervosa: a double-blind, placebo-controlled study.
Strokosch Gary R, Friedman Andrew J, Wu Shu-Chen et al. · J Adolesc Health · 2006
PMID: 17116511RCT
Effects of an oral contraceptive (norgestimate/ethinyl estradiol) on bone mineral density in women with hypothalamic amenorrhea and osteopenia: an open-label extension of a double-blind, placebo-controlled study.
Warren Michelle P, Miller K K, Olson W H et al. · Contraception · 2005
PMID: 16102557RCT
The paradigm of norgestimate: a third-generation testosterone-derivative progestin with a peripheral anti-androgenic activity and the lowest risk of venous thromboembolism.
Grandi Giovanni, Del Savio Maria Chiara, Facchinetti Fabio · Expert Rev Clin Pharmacol · 2021
PMID: 33464138Observational
A comparison of multiphasic oral contraceptives containing norgestimate or desogestrel in acne treatment: a randomized trial.
Jaisamrarn Unnop, Chaovisitsaree Somsak, Angsuwathana Surasak et al. · Contraception · 2014
PMID: 25074072Observational
Mood and physical symptoms improve in women with severe cyclical changes by taking an oral contraceptive containing 250-mcg norgestimate and 35-mcg ethinyl estradiol.
Nyberg Sigrid · Contraception · 2013
PMID: 23121822Observational
Effects of E2 and E2/norgestimate hormone therapy on elevated baseline lipids.
Langer Robert D, Friedman Andrew J · J Reprod Med · 2006
PMID: 16967629Observational

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Specialists

Providers who commonly manage this intervention

Obstetrics & Gynecology Physician

Obstetrics & Gynecology

NUCC 207V00000X
Reproductive Endocrinology Physician

Obstetrics & Gynecology — Reproductive Endocrinology

NUCC 207VE0102X
Find a Provider

Health Goals

Goals connected through associated conditions

Support Reproductive Health

Quick Facts

Type
Substance / Medication
Fully Specified Name
Norgestimate (substance)
SNOMED CT
126115000
UMLS CUI
C0068992
RxNorm CUI
31994

Clinical Data

This intervention maps to 7 entities in the Healos knowledge graph.

1
Conditions
3
Biomarkers
2
Specialists
0
Symptoms
2
Clinical Trials

Data is sourced from SNOMED CT, UMLS, and the Healos clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.